Difference between revisions of "Team:UCopenhagen"
| Line 167: | Line 167: | ||
<h2 class="section-heading">Incell: a platform for synthetic endosymbiosis</h2> | <h2 class="section-heading">Incell: a platform for synthetic endosymbiosis</h2> | ||
<p class="lead">Incell is a new synthetic biology platform with near future applications in research, industry and services. We are rewriting nature’s code for endosymbiosis and transforming an evolutionary phenomenon into a technology compatible with standard biological parts. | <p class="lead">Incell is a new synthetic biology platform with near future applications in research, industry and services. We are rewriting nature’s code for endosymbiosis and transforming an evolutionary phenomenon into a technology compatible with standard biological parts. | ||
| + | |||
Our vision is to produce synthetic host–endosymbiont systems. We set out with a trinity of experiments intrinsic to the synthetic reconstruction of endosymbiosis. First, creating and sustaining dependence between a host and its endosymbionts by fulfilling the amino acid requirement of an auxotrophic host. Next, to build a modular system of cell-penetrating peptides for protein transport of host nuclear encoded proteins into an endosymbiont, recapitulating a crucial feature of the natural process. Finally, regulating the number of endosymbionts within a host using a CRISPR-Cas system for control of replication. | Our vision is to produce synthetic host–endosymbiont systems. We set out with a trinity of experiments intrinsic to the synthetic reconstruction of endosymbiosis. First, creating and sustaining dependence between a host and its endosymbionts by fulfilling the amino acid requirement of an auxotrophic host. Next, to build a modular system of cell-penetrating peptides for protein transport of host nuclear encoded proteins into an endosymbiont, recapitulating a crucial feature of the natural process. Finally, regulating the number of endosymbionts within a host using a CRISPR-Cas system for control of replication. | ||
| + | |||
Further ahead we see a safe, customisable, sustainable technology providing biological solutions to present and future challenges in biotechnology, agriculture and medicine. | Further ahead we see a safe, customisable, sustainable technology providing biological solutions to present and future challenges in biotechnology, agriculture and medicine. | ||
Revision as of 15:47, 8 September 2017
<!DOCTYPE HTML>
